BIOQ Stock BIOQUAL (BIOQ, $40) was a top winner yesterday, jumping +8.11%

GET DAILY SIGNALS

Get AI intraday signals

BIOQ - BIOQUAL, Inc.

Loading...

Price: $40

Daily change: +$3 (+8.11%)

Daily volume: 1.1K

Capitalization: $35.8M

Industry: Medical Specialties

BIOQUAL (BIOQ, $40) was one of the top gainers yesterday, rising to $40 per share. A.I.dvisor analyzed 85 stocks in the Medical Specialties Industry and found that of them (4) are in an Uptrend while of them (5) are in a Downtrend.

BIOQ's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for BIOQ turned positive on November 26, 2025. Looking at past instances where BIOQ's MACD turned positive, the stock continued to rise in of 30 cases over the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Momentum Indicator moved above the 0 level on November 24, 2025. You may want to consider a long position or call options on BIOQ as a result. In of 38 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Bearish Trend Analysis

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (12.615). P/E Ratio (0.000) is within average values for comparable stocks, (138.269). BIOQ's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.935). Dividend Yield (0.013) settles around the average of (0.016) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (11.056).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. BIOQ’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIOQ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.